Hilleman M R
Merck Institute for Therapeutic Research, Merck Research Laboratories, West Point, PA.
Dev Biol Stand. 1994;82:3-20.
The development of recombinant vector vaccines will be guided by nearly two centuries of research in vaccinology and immunology. Experimental vector vaccines may be of viral, bacterial or genetic composition and their acceptability will depend on safety, efficacy, and practicality as seen by the user, the developer, and the licensing authority. Recombinant vector vaccines will need to compete with alternative vaccine approaches and may find special use for non-propagable agents, immunization in early life, fertility control, and emerging infectious agents. Needs of the developing nations that include low cost, temperature stability, and ease of administration may be met, in part at least, by the vector vaccine approach.
重组载体疫苗的研发将以近两个世纪的疫苗学和免疫学研究为指导。实验性载体疫苗可能具有病毒、细菌或基因组成，其可接受性将取决于使用者、开发者和许可机构所看到的安全性、有效性和实用性。重组载体疫苗将需要与其他疫苗方法竞争，并可能在不可传播病原体、早期免疫、生育控制和新兴传染病原体方面找到特殊用途。发展中国家的需求，包括低成本、温度稳定性和易于给药，至少部分可以通过载体疫苗方法来满足。
